- Trials with a EudraCT protocol (65)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
65 result(s) found for: Inhibitory control.
Displaying page 1 of 4.
EudraCT Number: 2013-002386-18 | Sponsor Protocol Number: 11-185/CAIAC | Start Date*: 2016-03-15 |
Sponsor Name:RWTH Aachen Clinical Trials Center Aachen (CTC-A) | ||
Full Title: Network connectivity and inhibitory control under atomoxetin challenge - A pharamacological "resting state" and "inhibitory task" fMRI study in patients with ADHD | ||
Medical condition: Patients with Attention-Deficit/Hyperactivity Disorders (ADHD) | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2007-001855-20 | Sponsor Protocol Number: Driving07 | Start Date*: 2009-02-03 |
Sponsor Name:Faculty of Social Sciences, Utrecht University | ||
Full Title: A double blind placebo controlled crossover study to determine the effects of atomoxetine on event-related potentials in response to auditory oddball stimuli during an on-the-road driving test in a... | ||
Medical condition: The effects of atomoxetine on driving performance, attention and response inbihition are studied in adult patients with attention-deficit hyperactivity disorder | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2010-023175-26 | Sponsor Protocol Number: P_TPT_2010 | Start Date*: 2011-01-14 | |||||||||||
Sponsor Name:Leiden University Medical Center | |||||||||||||
Full Title: Influence of Tapentadol on endogenous modulation of pain in chronic neuropathic pain patients and healthy volunteers | |||||||||||||
Medical condition: Chronic pain patients/ mhealthy volunteers | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-006633-41 | Sponsor Protocol Number: 310723 | Start Date*: 2007-04-11 | |||||||||||
Sponsor Name:Bayer Schering Pharma AG | |||||||||||||
Full Title: Monocenter, open-label, randomized study to determine the ovulation inhibitory effect of the combined oral contraceptives SH T04769G (0.015 mg Ethinylestradiol and 1.5 mg Dienogest in a modified re... | |||||||||||||
Medical condition: The aim of this monocenter, open-label, randomized study is to determine the ovulation inhibitory effect of the COC SH T04769G (0.15 mg Ethinylestradiol and 1.5 mg Dienogest in a modified release f... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-012586-55 | Sponsor Protocol Number: Protocol_DNIC_2009 | Start Date*: 2009-08-27 |
Sponsor Name:Leiden University Medical Center | ||
Full Title: Influence of S(+)-ketamine on Diffuse Noxious Inhibitory Control (DNIC) and offset analgesia (OA) in chronic pain patients (neuropathic pain, complex regional pain syndrome type 1, fibromyalgia) an... | ||
Medical condition: Chronic pain patients: CRPS-1, fibromyalgia and neurptahic pain | ||
Disease: | ||
Population Age: | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-003514-39 | Sponsor Protocol Number: GNCbumet | Start Date*: Information not available in EudraCT |
Sponsor Name:Gillberg Neuropsychiatry Centre | ||
Full Title: Testing E/I imbalance in autism with Bumetanide – a parallel group randomized waitlist-control trial in adolescents and adults | ||
Medical condition: Autism Spectrum Disorder | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2010-024108-84 | Sponsor Protocol Number: 071001 | Start Date*: 2011-10-31 | |||||||||||
Sponsor Name:Baxter Innovations GmbH | |||||||||||||
Full Title: A PHASE 3 CLINICAL STUDY TO DETERMINE THE PHARMACOKINETICS, SAFETY AND EFFICACY OF rVWF:rFVIII and rVWF IN THE TREATMENT OF BLEEDING EPISODES IN SUBJECTS DIAGNOSED WITH VON WILLEBRAND DISEASE | |||||||||||||
Medical condition: Von Willebrand Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) SE (Completed) AT (Completed) NL (Completed) BE (Completed) BG (Completed) IT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-003221-19 | Sponsor Protocol Number: 281101 | Start Date*: 2012-12-17 | |||||||||||
Sponsor Name:Baxalta Innovations GmbH | |||||||||||||
Full Title: BAX 930 (rADAMTS13) A PHASE 1 PROSPECTIVE, UNCONTROLLED, OPEN-LABEL, MULTICENTER, DOSE-ESCALATION STUDY EVALUATING THE SAFETY AND PHARMACOKINETICS IN HEREDITARY TTP (THROMBOTIC THROMBOCYTOPENIC PU... | |||||||||||||
Medical condition: Subjects diagnosed with hereditary thrombotic thrombocytopenic purpura (TTP) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) DE (Completed) GB (Completed) PL (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-005389-11 | Sponsor Protocol Number: VAC035 | Start Date*: 2009-05-07 | |||||||||||
Sponsor Name:University of Oxford | |||||||||||||
Full Title: A Phase I/IIa Study of the Safety, Immunogenicity and Parasite Growth Inhibitory Activity of AMA1-C1/Alhydrogel® + CPG 7909, an Asexual Blood Stage Vaccine for Plasmodium falciparum Malaria | |||||||||||||
Medical condition: Plasmodium falciparum malaria | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003742-16 | Sponsor Protocol Number: IB1001-04 | Start Date*: 2014-04-29 | |||||||||||
Sponsor Name:Cangene Europe Limited | |||||||||||||
Full Title: Pharmacokinetics, Safety and Efficacy of Recombinant Factor IX Product, IB1001, in Patients with Severe Hemophilia B | |||||||||||||
Medical condition: Severe Hemophilia B | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003775-35 | Sponsor Protocol Number: SHP655-201 | Start Date*: 2019-07-03 | |||||||||||
Sponsor Name:Baxalta Innovations GmbH | |||||||||||||
Full Title: A Phase 2, multicenter, randomized, placebo-controlled, double-blind study in patients with acquired thrombotic thrombocytopenic purpura (aTTP) to evaluate the pharmacokinetics, safety, and efficac... | |||||||||||||
Medical condition: acquired thrombotic thrombocytopenic purpura (aTTP) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-001514-34 | Sponsor Protocol Number: ILNK15-01 | Start Date*: 2012-04-03 | |||||||||||
Sponsor Name:Leiden University Medical Center | |||||||||||||
Full Title: Infusion of IL-15 activated NK cells after allogeneic stem cell transplantation in children transplanted for relapsed/refractory leukemia: a feasibility study | |||||||||||||
Medical condition: Children with high-risk and recurrent acute leukemia are eligible for allogeneic hematopoietic stem cell transplantation (HSCT). However, leukemia relapse and viral infections after HSCT remain mai... | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-005721-43 | Sponsor Protocol Number: D4280C00002 | Start Date*: 2012-05-14 |
Sponsor Name:AstraZeneca AB | ||
Full Title: A Phase III, Randomized, Multicenter, Double-Blind, Double Dummy, Parallel Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime-Avibactam (CAZ-AVI, formerly C... | ||
Medical condition: Complicated Urinary Tract Infections (cUTIs) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GR (Completed) BE (Completed) BG (Completed) DE (Completed) CZ (Completed) SK (Completed) PT (Completed) HU (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-000181-34 | Sponsor Protocol Number: OBI-1-301 | Start Date*: 2011-06-29 | |||||||||||
Sponsor Name:Baxter Innovations GmbH | |||||||||||||
Full Title: Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies | |||||||||||||
Medical condition: Acquired Haemophilia A | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) SE (Completed) DE (Completed) HU (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002236-24 | Sponsor Protocol Number: 261302 | Start Date*: 2014-03-27 | |||||||||||
Sponsor Name:Baxter Innovations GmbH | |||||||||||||
Full Title: A Phase 3b Continuation study of the Safety and Efficacy of PEGylated Recombinant Factor VIII (PEG-rFVIII; BAX 855) in Prophylaxis of Bleeding in Previously Treated Patients with Severe Hemophilia A | |||||||||||||
Medical condition: Severe hemophilia A (FVIII <1%) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: BE (Completed) LT (Completed) BG (Completed) SE (Completed) GB (Completed) CZ (Completed) AT (Completed) NL (Completed) DE (Completed) ES (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005722-21 | Sponsor Protocol Number: D4280C00004 | Start Date*: 2012-06-05 |
Sponsor Name:AstraZeneca AB | ||
Full Title: A Phase III, Randomized, Multicenter, Double-Blind, Double Dummy, Parallel Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime-Avibactam (CAZ-AVI, formerly C... | ||
Medical condition: Complicated Urinary Tract Infections (cUTIs) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GR (Completed) DE (Completed) CZ (Completed) ES (Completed) IT (Completed) BG (Completed) PL (Completed) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-000220-18 | Sponsor Protocol Number: C.2524.0472.01 | Start Date*: 2013-03-25 |
Sponsor Name:University of Amsterdam | ||
Full Title: Effects of melatonin treatment, light therapy, and sleep improvement on psychosocial, cognitive, and behavioural outcomes in children with Delayed Sleep Phase Syndrome and their parents | ||
Medical condition: Delayed Sleep Phase Syndrome | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2007-005789-11 | Sponsor Protocol Number: atorv02 | Start Date*: 2008-03-11 | |||||||||||
Sponsor Name:RUNMC | |||||||||||||
Full Title: Does atorvastatin have an acute and prolonged inhibitory effect on ischemia-reperfusion injury in humans in-vivo? | |||||||||||||
Medical condition: ischemia-reperfusion injury | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002578-37 | Sponsor Protocol Number: OPHT-240518 | Start Date*: 2019-04-25 |
Sponsor Name:Medical University of Vienna, Department of Clinical Pharmacology | ||
Full Title: The effect of antibiotic eye drops on the nasal microbiome in healthy subjects | ||
Medical condition: healthy volunteers | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2010-022726-33 | Sponsor Protocol Number: 251001 | Start Date*: 2011-03-24 | |||||||||||
Sponsor Name:Baxter Innovations GmbH | |||||||||||||
Full Title: BAX326 (recombinant Factor IX): Evaluation of Safety, Immunogenicity, and Hemostatic Efficacy in Previously Treated Patients with Severe (FIX level < 1%) or Moderately Severe (FIX level 1- 2%) Hemo... | |||||||||||||
Medical condition: Previously treated patients (PTPs) with severe (FIX level < 1%) or moderately severe (FIX level 1- 2%) hemophilia B. | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) CZ (Completed) GB (Completed) DE (Prematurely Ended) SE (Completed) PL (Completed) ES (Completed) IT (Completed) IE (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
